Joanne Jenkins Lager - 18 Nov 2021 Form 4 Insider Report for iTeos Therapeutics, Inc. (ITOS)

Role
Chief Medical Officer
Signature
/s/ Adi Osovsky, as Attorney-in-Fact
Issuer symbol
ITOS
Transactions as of
18 Nov 2021
Net transactions value
-$845,600
Form type
4
Filing time
19 Nov 2021, 19:00:20 UTC
Previous filing
25 Jun 2021
Next filing
10 Dec 2021
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ITOS Common Stock Options Exercise $120,400 +28,000 $4.30 28,000 18 Nov 2021 Direct F1
transaction ITOS Common Stock Sale $966,000 -28,000 -100% $34.50 0 18 Nov 2021 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ITOS Stock Option (right to buy) Options Exercise $0 -28,000 -12% $0.000000 206,938 18 Nov 2021 Common Stock 28,000 $4.30 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 23, 2021.
F2 One-fourth of the shares subject to the stock option vested on April 1, 2020. Thereafter, 1/48 of the shares subject to the stock option vest on a monthly basis, subject to the reporting person's continuous service relationship with the Issuer through each applicable vesting date.